Insmed price target raised to $82 from $36 at Mizuho

Mizuho raised the firm’s price target on Insmed to $82 from $36 and keeps a Buy rating on the shares following the announcement of positive Phase 3 data for brensocatib last week. The firm says its updated model now reflects the full potential of brensocatib, “a product that holds the cards in completely transforming the prospects” of the company. It notes it new price target is the high on the Street.